TARS TARSUS PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, TARSUS PHARMACEUTICALS INC reported revenue of $174M (up 69.4% from a year earlier), net income of −$18.6M and diluted EPS of −$0.43; over the last four quarters revenue was $606M and net income −$46.1M; for the fiscal year ended December 2025 revenue was $451M, up 146.7% on the year before.
TARS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $451M, gross profit n/a, operating income −$71.0M, net income −$66.0M (margin -14.6%), EPS −$1.59
- Fiscal year ended Dec 2024: revenue $183M, gross profit n/a, operating income −$121M, net income −$116M (margin -63.4%), EPS −$3.07
- Fiscal year ended Dec 2023: revenue $17.4M, gross profit n/a, operating income −$143M, net income −$136M (margin -779.5%), EPS −$4.62
- Fiscal year ended Dec 2022: revenue $25.8M, gross profit n/a, operating income −$62.7M, net income −$62.1M (margin -240.5%), EPS −$2.52
- Fiscal year ended Dec 2021: revenue $57.0M, gross profit n/a, operating income −$12.2M, net income −$13.8M (margin -24.2%), EPS −$0.67
TARS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $174M (up 69.4% year over year), net income −$18.6M, EPS −$0.43
- Quarter ended Mar 31, 2026: revenue $162M (up 106.9% year over year), net income −$6.97M, EPS −$0.16
- Quarter ended Dec 31, 2025 (from the annual report): revenue $152M (up 128.4% year over year), net income −$7.96M, EPS −$0.17
- Quarter ended Sep 30, 2025: revenue $119M (up 146.7% year over year), net income −$12.6M, EPS −$0.30
- Quarter ended Jun 30, 2025: revenue $103M (up 151.5% year over year), net income −$20.3M, EPS −$0.48
- Quarter ended Mar 31, 2025: revenue $78.3M (up 183.7% year over year), net income −$25.1M, EPS −$0.64
- Quarter ended Dec 31, 2024 (from the annual report): revenue $66.4M (up 407.9% year over year), net income −$23.6M, EPS −$0.57
- Quarter ended Sep 30, 2024: revenue $48.1M (up 2471.8% year over year), net income −$23.4M, EPS −$0.61
- Quarter ended Jun 30, 2024: revenue $40.8M, net income −$33.3M, EPS −$0.88
- Quarter ended Mar 31, 2024: revenue $27.6M (up 1004.6% year over year), net income −$35.7M, EPS −$1.01
- Quarter ended Dec 31, 2023 (from the annual report): revenue $13.1M (up 30.8% year over year), net income −$42.0M, EPS −$1.29
- Quarter ended Sep 30, 2023: revenue $1.87M, net income −$39.1M, EPS −$1.28
- Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$31.4M, EPS −$1.17
- Quarter ended Mar 31, 2023: revenue $2.50M (up 363.8% year over year), net income −$23.4M, EPS −$0.88
- Quarter ended Dec 31, 2022 (from the annual report): revenue $10.0M (up 2858.6% year over year), net income −$13.6M, EPS −$0.46
- Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$22.5M, EPS −$0.84
- Quarter ended Jun 30, 2022: revenue $15.3M (down 30.6% year over year), net income −$5.74M, EPS −$0.24
- Quarter ended Mar 31, 2022: revenue $539K (down 98.4% year over year), net income −$20.2M, EPS −$0.98
- Quarter ended Dec 31, 2021 (from the annual report): revenue $338K, net income −$14.9M, EPS −$0.67
- Quarter ended Sep 30, 2021: revenue $1.24M, net income −$15.7M, EPS −$0.76
TARS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.5M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$83.0M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$117M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$49.0M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow $3.75M, share buybacks n/a, dividends $0.00 per share
TARS balance sheet
- Jun 30, 2026: cash $205M, total assets $611M, total liabilities $264M, shareholders' equity $347M, long-term debt $72.8M
- Mar 31, 2026: cash $102M, total assets $581M, total liabilities $232M, shareholders' equity $349M, long-term debt $72.6M
- Dec 31, 2025: cash $184M, total assets $562M, total liabilities $219M, shareholders' equity $343M, long-term debt $72.4M
- Sep 30, 2025: cash $113M, total assets $535M, total liabilities $199M, shareholders' equity $335M, long-term debt $72.3M
- Jun 30, 2025: cash $96.6M, total assets $495M, total liabilities $162M, shareholders' equity $333M, long-term debt $72.1M
- Mar 31, 2025: cash $176M, total assets $501M, total liabilities $158M, shareholders' equity $342M, long-term debt $72.0M
- Dec 31, 2024: cash $94.8M, total assets $377M, total liabilities $152M, shareholders' equity $225M, long-term debt $71.8M
- Sep 30, 2024: cash $176M, total assets $376M, total liabilities $139M, shareholders' equity $237M, long-term debt $71.7M
What is TARS's revenue?
TARSUS PHARMACEUTICALS INC reported $606M of revenue over its last four quarters, through June 30, 2026.
Is TARS profitable?
No. TARSUS PHARMACEUTICALS INC lost $46.1M over the last four quarters.
What is TARS's EPS?
Diluted earnings per share over the last four quarters were −$1.06; −$0.43 in the latest quarter.